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A 43-year-old woman recipient of a bare metal coronary stent during an acute anterior myocardial infarction was
repeatedly hospitalized with recurrent stent thrombosis (ST) over the following 3 years. Emergent coronary
angiography showed a thrombus in the in-stent segment of the proximal left anterior descending artery. We
repeatedly aspirated the thrombus, which immediately reformed multiple times. The discontinuation of heparin and
administration of thrombolytics and argatroban, followed by repeated balloon dilatations, ended the formation of
new thrombi. The patient was found to be allergic to nickel, protein S deficient and carrier of heparin-induced
thrombocytopenia antibody. We discuss this case in the context of a) literature pertaining to acute coronary
syndromes in the young, and b) the detailed investigations needed to identify thrombotic risk factors. Steroids may
be effective to prevent recurrent ST caused by stent allergy.
Keywords: Stent thrombosis, Metal allergy, Heparin-induced thrombosis, Protein S deficiencyBackground
Stent thrombosis (ST) is a rare though critical complica-
tion of PCI, which may occur despite recent progress in
antiplatelet therapy and procedural techniques. The inci-
dence of ST ranges between 0.6 and 4.4 % [1–5]. How-
ever, the clinical consequences of ST include myocardial
infarction in 70 % to 80 % or death in 30 % of cases [6].
Therefore, ST remains an important clinical challenge in
the modern era of stent deployment. There are many
patient-related potential factors of ST such as smoking,
diabetes mellitus, chronic kidney disease and premature
discontinuation or cessation of dual antiplatelet therapy
[7]. So far, however, no reports exist mentioning ST
caused by metal allergy complicated by protein S defi-
ciency and heparin-induced thrombocytopenia.* Correspondence: takaokonishi0915@gmail.com
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A 43-year-old woman was admitted to the coronary care
unit, complaining of prolonged chest pain that developed
while playing a mobile game at home. Acute coronary
syndrome (ACS) was diagnosed from the electrocardio-
gram, which showed a 1-mm ST segment elevation in the
precordial leads V1–V4 and reciprocal, 1-mm ST segment
depression in leads I and aVL, with abnormal Q waves in
V1–V3. Her coronary risk factors were dyslipidaemia and
current smoking. She had undergone a) implantation of a
4.0 × 18.0 mm Driver™ (Medtronic, Inc., Minneapolis,
MN) bare metal stent in the proximal left anterior de-
scending (pLAD) artery 3 years earlier for management of
a first ACS with myocardial infarction, and b) percutan-
eous coronary intervention (PCI) and thrombus aspiration
12 months later for treatment of a 2nd ACS due to in-
stent thrombosis. After having being treated with warfarin
for 2 years to prevent ST, the international normalized ra-
tio had fallen between 1.1 and 1.3 (below the optimal
therapeutic range), because of anaemia due to abundantrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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treatment of her 3rd ACS.
On physical examination, her pulse was 80 bpm, blood
pressure 128/83 mmHg, and a 3rd heart sound was aud-
ible on auscultation. The laboratory tests revealed a
21.0 × 103/μl white blood cell count with 96.5 % neutro-
phils, a platelet count of 42.2 × 104/μl, a 7.3 g/dl haemo-
globin concentration, 63.0 and 5.3 IU/l, CK and CK-MB
concentrations, respectively, negative H-FABP, and 0.8 μg/
ml d-dimer and 0.02 mg/dl C-reactive protein serum con-
centrations. She immediately received 5,000 units of
unfractionated heparin in a single bolus, followed by an-
other 5,000 units bolus in the catheterization laboratory,
before undergoing emergent coronary angiography, which
revealed the presence of stent thrombosis (ST) and TIMI
2 distal flow in the pLAD artery (Fig. 1). An intravascular
ultrasound study showed an in-stent fibrous thrombus in
the pLAD artery (Fig. 2). After each aspiration of the
thrombus with a special catheter, a large, red thrombus
reappeared, requiring 10 consecutive aspirations over
45 min (Fig. 3). Suspecting heparin-induced thrombocyto-
penia (HIT), we discontinued the administration of hep-
arin and substituted argatroban. Balloon angioplasty was
performed, without further recurrence of thrombus, and
the patient, finally chest pain free, stabilized clinically and
was discharged from the hospital on the 27th day on a
regimen of dabigatran instead of warfarin.
During her hospitalization, the patient underwent in-
vestigations of the cause of ST, including a patch test,
blood coagulation test and HIT antibody. The skin patch
test showed a positive response to nickel, a metal in-
cluded in the composition of the Driver stent. Protein C,
antithrombin III, antinuclear antibody, anticardiolipin 2-
glycoprotein I complex antibody and lupus anticoagulant
were within normal limits, though the concentration of
protein S (PS) was 35 % (normal = 60–150 %), total PSFig. 1 Coronary angiography. a. Right anterior oblique and caudal view. b.
(arrowheads) in the in-stent segment of the proximal left anterior descendantigen was 56 % (normal = 65–135 %) and free PS anti-
gen was 50 % (normal = 60–150 %). PS deficiency is clas-
sified as type I (decreased concentration of total and free
PS antigen), type II (decreased activity of activated pro-
tein C-cofactor and normal total and free PS antigen
concentration), and type III (decreased concentration of
free PS antigen only) [8]. This patient presented with
type I PS deficiency. The HIT test showed a weakly posi-
tive reaction: IgG・IgM・IgA 1.3 U/ml (normal ≤1.0 U/
ml). Intravascular ultrasound study during PCI showed no
incomplete stent apposition or stent fracture. The patient had
been compliant with antiplatelet therapy before her admis-
sion to the hospital, including aspirin 100 mg/day and clopi-
dogrel 75 mg/day, and was not using oral contraception.
The patient was discharged from the hospital on a
regimen of dabigatran, 300 mg/day, later replaced by riv-
aroxaban, 15 mg/day, instead of warfarin. However, she
suffered a 4th ST in the pLAD artery 4 months later
and, despite the prescription of the anti-allergic agent,
fexofenadine, 120 mg/day, she experienced a 5th ST
1 month later. Prednisolone, gradually tapered from 25
to 5 mg/day, was added and the patient remained free
from ST over a >18-month follow-up. This clinical
course suggested that her recurrent thrombotic events
were caused mainly by a stent allergy, and that PS defi-
ciency and HIT are associated with ST.
Discussion
The pathophysiology of ST includes lesion-, stent-,
procedure-, and patient-related factors. Early ST are
often associated with lesion—or procedural factors, such
as insufficient expansion of the stent, edge dissection,
compromised flow and location of the stent at a bifur-
cation [9]. On the other hand, late and very late ST are
associated with a variety of causes, such as local hypersen-
sitivity reaction, poor endothelialization, inflammation,Left anterior oblique and cranial view. A stent thrombosis is visible
ing artery
Fig. 2 Intravascular ultrasound. Fibrous thrombi are visible in the in-stent segment of the pLAD artery
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best of our knowledge, this is the first report of ST caused
by metal allergy complicated by PS deficiency and HIT in
a young woman.
Stent allergy
ST or in-stent restenosis (ISR) due to stent allergy have
been reported [12–15]. Aliagaoglu et al. reported nickel
allergies confirmed by patch tests in 7 of 31 patients
(23 %) who developed ISR, while none of 30 patients freeFig. 3 Aspirated thrombi. a. Several large thrombi (arrow) were aspirated d
device. b. Extracted thrombi on a Petri dishfrom ISR had an allergy to nickel (p < 0.01) [12]. Koster
et al. reported that 10 of 89 patients (11 %) who developed
restenosis after PCI had positive reactions to nickel or mo-
lybdenum, which are standard components of metal stents
[14]. Furthermore, the prevalence of nickel allergy in the
general population is as high as 17 % in women and 3 %
in men [16]. These observations suggest that stent allergy
is an important risk factor of ST.
The mechanism of ST caused by metal allergy is a
local endothelial inflammation and excessive immuneuring PCI and preserved in physiologic saline inside the aspiration
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nickel, the metal is steadily released into the systemic
circulation, promoting the expression of intercellular ad-
hesion molecule-1 on endothelial cells, which plays an
important role in the recruitment of inflammatory cells
from the bloodstream [17, 18]. In addition, local expos-
ure to a stent containing nickel causes a type IV hyper-
sensitivity mediated by allergen-specific T lymphocytes,
which can trigger excessive immunologic reactions [19, 20].
Once nickel sensitization has occurred, it may persist for
many years [21]. Since the bare metal stent implanted in
this patient contained cobalt, nickel, chromium and mo-
lybdenum, a risk of ST was present since the stent im-
plantation 3 years earlier. Therefore, patients who develop
repetitive ST after implantation should undergo patch
testing in search of metal allergy.
A significant increase in white blood cells, including eo-
sinophils, does not occur systematically after implantation
of coronary stents in metal allergic patients presenting
with ISR [22]. Because of a paucity of Langerhans cells
compared to the skin, the placement of stents in the cor-
onary vessels triggers a weak immunological response
[21]. Therefore, it is likely that, as illustrated in this case,
an allergy to a metallic stent triggers an increase in eosino-
phil count consistent with a local instead of a systemic al-
lergic reaction. In a post mortem study, eosinophilic
infiltrations were observed at the site of the stent in pa-
tients with ST associated with stent allergies [23]. In our
case, the histology showed eosinophilic infiltrates in part
of the aspirated thrombus (Fig. 4), suggesting that a local
stent allergic reaction was associated with ST.Fig. 4 Histological examination of aspirated thrombi. a. High-power (origin
inflammatory cells in aspirated fibrin-rich thrombus as observed after haem
400×) microphotograph showing the eosinophilic infiltration as observed aSince inflammation is one of the main causes of ST or
ISR [24, 25], the systemic administration of anti-
inflammatory or immunosuppressive therapy might be
appropriate when a metal allergy is confirmed or strongly
suspected. The implantation of a stent causes a prolonged
recruitment of inflammatory cells [26]. In recent studies,
the administration of oral steroids after PCI suppressed
the vascular inflammation and lowered the rates of ST,
ISR, or both [27–33]. For example, in the CEREA-DES
trial, the adverse event-free survival of 125 recipients of
bare metal stent alone was 75 %, versus 84 % in 125
prednisone-treated patients, a significant difference [32].
Chronic inflammation and endothelial dysfunction induce
neoatherosclerosis on the long term inside both bare
metal stent and drug eluting stent (DES), and the disrup-
tion of neoatherosclerotic plaques plays an important role
in the occurrence of late, and especially, very late ST [11,
34–36]. Considering that, in our patient, ST developed 5
times since the stent implantation, 3 years earlier, we
hypothesize that a local inflammation caused by stent al-
lergy promoted a persistent thrombogenic propensity and
multiple thrombotic events during that period.
While warfarin or new oral antithrombotic agents
must be administered in patients who develop ST after
PCI [37–39], low-dose steroids in addition to dual anti-
platelet therapy might prove effective, especially for pa-
tients who develop ST due to stent allergy, provided
they do not suffer from diabetes or other contraindica-
tions to steroids. Unlike pharmacologic doses of gluco-
corticoids, which seem to increase the risk of adverse
cardiovascular events [40], low doses of steroids mightal magnification 400×) microphotograph showing the infiltration of
atoxylin and eosin staining. b. High-power (original magnification
fter Giemsa staining (between arrowheads)
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their anti-inflammatory properties. The relative risk of
adverse cardiovascular events in recipients of ≥7.5 mg of
prednisolone equivalent on the long term was 2.56 [40].
In contrast, in another study, oral prednisone lowered
significantly the cumulative incidence of major adverse
cardiovascular events, including ST [32]. The prednisone
regimen consisted of 1 mg/kg for the first 15 days after
stent implantation, 0.5 mg/kg from day 16 to day 30,
and 0.25 mg/kg from day 31 to day 40. In this patient,
an initial dose of 25 mg/day of prednisolone was tapered
by 5 mg every month to a maintenance dose of 5 mg/
day. The dose of prednisolone remained unchanged and
no further ST was observed.
Stent extraction followed by coronary artery bypass graft
is an alternate means of management of ST due to stent
allergy [41–43]. Likewise, recent studies have reported a
low incidence of ST after implantation of bioresorbable
vascular scaffolds, which may be particularly useful in
patients presenting with stent allergy undergoing PCI
[44, 45]. After the elution of the anti-proliferative drug and
the resorption of the scaffold, the risk of STcaused by metal
allergy is markedly decreased. A direct comparison of antic-
oagulation versus resorbable stent versus steroid therapy
would be of great interest to determine which is the most
effective prevention of ST associated with stent allergy.
Heparin-induced thrombocytopenia
The incidence of heparin-induced thrombocytopenia
(HIT) ranges between 0.3 and 5.0 % of patients exposed to
unfractionated heparin [46–48]. Women are more likely
than men to develop HIT with an approximate relative
risk of 1.5 to 2.0 [49, 50]. HIT is closely associated with
thrombotic events, with a 20–40 odds ratio for throm-
bosis, and a thrombotic risk ranging between 38 and 76 %
[50] and a 10.2 % mortality rate [51]. Therefore, a prompt
diagnosis of HIT is key when patients administered hep-
arin present with thrombocytopenia or thrombosis.
While the platelet count in this patient was within
normal limit, the relative change in platelets instead of
the absolute platelet count must be ascertained [52, 53].
The evolution of our patient’s platelet count is shown in
Fig. 5. A “4T” scoring system, widely used for the clinical
diagnosis of HIT, includes 1) the degree of Thrombocyto-
penia, 2) the Timing of the fall in platelet count after hep-
arin exposure, 3) the presence of Thrombosis, and 4) the
exclusion of oTher causes of thrombocytopenia [54]. Our
patient’s 4T score was 5 out of 8, consistent with an inter-
mediate probability of HIT. The positive predictive value
of an intermediate 4T score in a population at relatively
high risk of HIT is approximately 45 % [55]. The HIT Ex-
pert Probability score, based on the opinions of 26 expert
clinicians [56], is a new pre-test probability model, which,
using a cut-off score of 5, has been associated with a100 % sensitivity, 60 % specificity and 55 % positive pre-
dictive value in the detection of HIT [56]. The likelihood
of HIT in our patient seemed relatively high, as her calcu-
lated score was 9. Her clinical presentation was also con-
sistent with a relationship between HIT and acute
coronary thrombosis during PCI. The administration of
argatroban after the discontinuation of heparin prevented
the formation of new thrombi during PCI. Furthermore,
the platelet count decreased consistently when she was
hospitalized and was administered heparin during emer-
gent PCI or follow-up coronary angiography (Fig. 5).
However, because her baseline platelet count was high
and the lowest counts remained within normal limits, the
cause of transient fall in platelet count was not recognized
and investigated until the third hospitalization for ACS.
In presence of circulating HIT antibodies from a re-
cent heparin exposure, a rapid-onset type of HIT usually
develops within minutes or hours after the beginning of
heparin treatment. Once the antibodies are formed, they
may persist for up to 100 days after the administration
of heparin [57]. Since the last ACS occurred approxi-
mately 2 years earlier, this seemed to be an atypical case
of rapid onset. However, the minuscule doses of heparin
contained in the heparin-coated infusions or heparin
flushes of intravenous iron preparation she had received
nearly monthly for abundant menstrual bleeding (Fig. 5)
might have unknowingly activated the HIT antibodies.
HIT antibodies may be activated more prominently by
high than by low doses of intravenous heparin, although
this has not been prospectively examined in a large
study. In a study by Chong, the incidence of HIT ranged
between 1 and 30 % among patients who received high
doses of intravenous heparin, in contrast with <2 % in
patients who received low doses of subcutaneous heparin
[58]. Our patient received a bolus of 10,000 IU of unfrac-
tionated heparin during the PCI for the 3rd ACS, com-
pared with 1,500–6,000 IU during the previous coronary
angiograms or PCI (Fig. 5). This different dose of heparin
might explain why a ST occurred during that PCI, and did
not occur during the previous angiograms or PCI.
Since they interact with neither platelet factor 4 (PF4)
nor anti-PF4/heparin antibodies, the new oral antithrom-
botics may be a valuable therapeutic alternative for pa-
tients who present with a history of HIT [59–61]. In our
patient, warfarin was replaced by dabigatran at the time of
hospital discharge and, later, dabigatran was replaced by
rivaroxaban to promote compliance with treatment.
Protein S deficiency
The estimated prevalence of PS deficiency in the general
population is 1–2 % [62–64]. PS is a plasma protein that
serves as a cofactor for the anticoagulant effects of acti-
vated protein C, which exists in 2 forms in plasma. Ap-
proximately 60 % of PS is bound to the complement
Table 1 Plasma factors influencing the thrombophilic propensity
Test Values (percent) Normal range (percent)
Total protein S antigen 56 65–135
Free protein S antigen 50 60–150
Protein S activity 35 60–150
Protein C activity 89 64–146
Anti-thrombin III activity 95 80–130
Factor X 81 70–130
Fig. 5 Evolution of platelet count. The platelet count decreased after each administration of heparin for emergent PCI or follow-up coronary
angiography. However, the fall in platelet count was not recognized until the 3rd hospitalization for ACS as the baseline platelet count was high
and the lowest count during each admission remained within normal limits. The patient received iron intravenously nearly every month for 3 years
for profuse menstrual bleeding, which might have activated circulating HIT antibodies. This patient received 10,000 IU of total unfractionated
heparin during PCI on the third ACS, higher than during previous angiographies or PCI (1,500–6,000 IU). ACS = acute coronary syndrome; CA =
coronary angiography; UFH = unfractionated heparin; Plt = platelet
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is free [65]. PS C4b binding protein has a direct anticoagu-
lant activity, although is less effective than free PS [66].
Recent studies have, in fact, found that free PS is a better
indicator of thrombotic events than total PS [67, 68].
It is likely that, compared with other vitamin K-
dependent proteins, the blood concentration of PS in
this patient was relatively decreased. Although PS is a
vitamin K-dependent coagulation factor, the antigen and
activity of which are significantly reduced upon the initi-
ation of warfarin therapy [69–71], its concentration is
also decreased during long-term anticoagulation with
warfarin [72–75]. Consequently, an accurate diagnosis of
PS deficiency based on its blood concentrations may be
challenging. We recommend comparing the relative
changes in PS concentration with that of other vitamin
K-dependent proteins, such as prothrombin, factors VII,
IX and X. Table 1 lists the plasma factors that influenced
this patient’s thrombophilic tendency. It is noteworthy
that all measurements of PS concentrations were decreased,
whereas the activities of factor X and protein C both
remained within normal limits.PS deficiency is a risk factor for deep venous thrombosis
and pulmonary thromboembolism, as well as arterial
thrombosis, including myocardial infarction [64, 76–79]
and, in some studies has been associated with a promin-
ently increased risk of ST [80, 81]. Since the PS activity of
patients with a hereditary deficiency is 25 to 40 % of that
measured in normal individuals [8] while the PS concen-
tration in patients treated with warfarin is decreased by
approximately 50 % [82], it is likely that, in this patient, PS
had decreased enough to cause a thrombotic event. The
hypercoagulable state due to the low PS concentration
measured in this patient seems to have outweighed the
Konishi et al. Thrombosis Journal  (2015) 13:25 Page 7 of 9anticoagulant effect of warfarin. Thus, she might have de-
veloped a significant protein S deficiency and recurrent
ST while receiving inadequate doses of warfarin. The dis-
continuation of warfarin and its replacement by a new
antithrombotic agent gradually normalized the PS concen-
trations, from 64 % at 1 month, to 78 % at 4 months after
her discharge from the hospital.
This patient suffered from an accelerated blood coagu-
lation caused by a combination of a) persistent local
inflammation due to stent allergy, b) HIT-associated hy-
percoagulability, and c) warfarin-induced protein S defi-
ciency. The intra-procedural ST was probably caused
mainly by HIT after the injection of heparin during PCI.
Heparin was replaced by argatroban and warfarin by a
new antithrombotic agent. However, ST recurred twice
despite the administration of the new antithrombotic
and anti-allergic pharmaceutical, though not after the
initiation of steroid therapy, suggesting that 1) the
thrombotic events were caused mainly by a stent allergy,
and 2) PS deficiency and HIT were associated with ST.Conclusions and clinical implications
While venous thrombosis and gangrene caused by HIT
and PS deficiency have been reported [83, 84], this is the
first case of ST associated with metal allergy in addition
to HIT and PS deficiency. Our observations suggest that
an allergy to the stent should be considered as a possible
cause of recurrent ST after stent implantation in rela-
tively young patients, who should undergo patch testing.
In addition, a history of metal allergy should be meticu-
lously explored before elective PCI. Besides antiplatelet
therapy, steroids may effectively prevent ST caused by a
metal allergy. Detailed examinations and the early identi-
fication of other aetiologies can prevent recurrent major
thrombotic events. It is noteworthy that, once formed,
circulating HIT antibodies may be activated by the regu-
lar use of heparin-coated vascular access, persist for
years, and be the cause of life-threatening thrombotic
events. When acute coronary thrombosis occurs during
PCI, HIT should always be strongly considered, since the
failure to promptly discontinue all heparin administra-
tion and initiate an alternate antithrombotic agent may
the source of major morbidity and mortality.Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images.
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